STOCK TITAN

Electromed - ELMD STOCK NEWS

Welcome to our dedicated page for Electromed news (Ticker: ELMD), a resource for investors and traders seeking the latest updates and insights on Electromed stock.

Overview

Electromed Inc is a Minnesota-based company specializing in the development, manufacturing, and global distribution of innovative medical devices focused on airway clearance therapy. At the heart of its product lineup is the cutting-edge SmartVest Airway Clearance System, which utilizes high frequency chest wall oscillation (HFCWO). This patented technology is designed to deliver effective yet comfortable treatment for patients suffering from conditions that result in compromised pulmonary function.

Core Technology and Product Offerings

The SmartVest system is a hallmark of medical device innovation in pulmonary care. It works by generating programmed air pulses through a specially designed garment, which is worn comfortably over the upper body. This process facilitates vigorous mucus clearance, thereby helping to manage symptoms associated with chronic respiratory conditions such as COPD, cystic fibrosis, bronchiectasis, atelectasis, and neuromuscular disorders.

  • High Frequency Chest Wall Oscillation (HFCWO): A key technological feature that offers an effective alternative to traditional chest physiotherapy.
  • Comfort and Safety: The design ensures that therapy remains well tolerated, promoting compliance among patients.
  • Clinical Validation: The treatment modality has been clinically tested to demonstrate its efficacy in clearing airway secretions and reducing lung infections.

Business Model and Market Position

Electromed generates revenue primarily through the direct sale of its SmartVest system and related products. The company is positioned within the broader healthcare technology and medical devices industry, where stringent regulatory standards and clinical efficacy are paramount. A significant aspect of the company’s market presence involves the continuous commitment to enhancing patient care by using technology that provides a safer and more effective treatment option than conventional methods.

Regulatory and Quality Standards

In the realm of medical devices, adherence to quality and safety protocols is crucial. Electromed maintains a robust certification profile, being accredited by the Joint Commission and certified to standards such as ISO 13485:2003 and ISO 9001:2008. These credentials attest to the company’s adherence to rigorous manufacturing processes and quality management systems, which are essential for ensuring the reliability and safety of its products.

Clinical Impact and Patient Benefits

The clinical utility of the SmartVest system is underscored by its ability to manage and alleviate the symptoms of a variety of pulmonary disorders. Patients benefit from a treatment that is not only effective in clearing airways but also designed to maximize comfort and usability. The system’s evolution reflects innovative responsiveness to clinical needs, contributing to improvements in patient quality of life and overall respiratory health management.

Industry Standing and Competitive Landscape

Within the competitive landscape of airway clearance solutions, Electromed distinguishes itself through its focus on combining technological innovation with stringent quality control. The company’s emphasis on safety, regulatory compliance, and clinical efficacy positions it as a trusted entity among healthcare providers and patients. While the market comprises various devices aiming to improve pulmonary function, Electromed’s strategic focus on HFCWO and its proven clinical benefits set it apart as a specialized and reliable provider.

Expertise and Authoritativeness in Healthcare Technology

Electromed Inc demonstrates a profound commitment to enhancing treatment regimens for respiratory disorders through its advanced medical technologies. Its products are firmly rooted in clinical research and regulatory best practices, making them a reference point for experts in the field. The company’s dedication to meeting high standards of performance and safety underscores its reputation for excellence in healthcare technology.

Summary

The innovative approach adopted by Electromed Inc, particularly through its SmartVest system, reflects its deep-rooted expertise in airway clearance therapy. The company manages to effectively combine state-of-the-art technology with a rigorous quality system to offer a product that improves respiratory care for individuals with complex pulmonary conditions. This comprehensive approach, backed by clinical validation and high regulatory standards, makes Electromed a distinctive presence in the medical device industry.

Rhea-AI Summary

Electromed, a leader in innovative airway clearance technologies, announced its participation in the Canaccord Genuity 44th Annual Global Growth Conference in Boston from August 13-15, 2024. Jim Cunniff, President and CEO, and Brad Nagel, CFO, will present on Wednesday, August 14, 2024, at 2:30 p.m. Eastern Time.

The presentation will be available via live and archived webcast on Electromed's website under Events & Presentations. Additionally, Electromed has published an updated investor presentation deck for review, accessible on their website and the SEC website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

Electromed, known for its innovative airway clearance technologies, announced that its top executives, President and CEO Jim Cunniff and CFO Brad Nagel, will attend the 2024 Sidoti June Small-Cap Virtual Conference. This event is scheduled for June 12-13, 2024. Electromed will present at 1:45 p.m. ET on June 12, 2024. A live and archived webcast of their presentation will be accessible via the Electromed website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.46%
Tags
conferences
-
Rhea-AI Summary

Electromed, Inc. achieves record revenue in the third quarter of fiscal year 2024, with a 15% increase to $13.9 million compared to the prior year. Operating income rises by 54%, net income reaches $1.49 million, and cash balance grows to $11.7 million. The company's direct homecare business revenue increases by 12%, showing strong growth and operational efficiency. The gross profit margin remains stable at 75%. Electromed continues to focus on driving adoption of its products, enhancing shareholder value, and sustaining operating leverage for profitability.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
Rhea-AI Summary
Electromed, Inc. announced the schedule for its Third Quarter Fiscal 2024 Financial Results Conference Call on May 7, 2024, at 5:00 p.m. ET. Interested parties can dial in or access the webcast to discuss the financial results for the fiscal quarter ended March 31, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.26%
Tags
-
Rhea-AI Summary
Electromed, Inc. (NYSE American: ELMD) announced that its President and CEO, Jim Cunniff, and CFO, Brad Nagel, will attend the 2024 Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 17-18, 2024. The management team will present at 10:30 a.m. Eastern Time on April 18, 2024. Interested individuals can register for the free webcast to view the presentation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
conferences
-
Rhea-AI Summary
Electromed, Inc. (ELMD) executives to attend 2024 Sidoti March Small-Cap Virtual Conference. Webcast available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.8%
Tags
conferences
Rhea-AI Summary
Electromed, Inc. announces record revenue in Q2 FY 2024, with a 17% increase to $13.7 million. Gross margins improved to 77%, while operating income reached $2.26 million. Net income was $1.67 million, with cash at $10.4 million. The company attributes growth to product development and market expansion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.92%
Tags
-
Rhea-AI Summary
Electromed, Inc. announced the release of its financial results for the fiscal 2024 second quarter, with a conference call scheduled to discuss the results. The call will take place on February 13, 2024, at 5:00 p.m. Eastern Time, and interested parties can participate via phone or webcast. A replay of the call will also be available for those who cannot listen to the live broadcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
-
Rhea-AI Summary
Electromed, Inc. (ELMD) has entered into a distribution agreement with Marathon Medical Corp., a service-disabled veteran-owned small business, to distribute its SmartVest® Airway Clearance System for High Frequency Chest Wall Oscillation therapy. This partnership aims to provide easier access to the therapy for government facilities, including VA hospitals and clinics, Indian Health Service hospitals and clinics, and other Federal agencies, ultimately improving the quality of life for US veterans, Federal employees, and Native American peoples.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.18%
Tags
partnership
Rhea-AI Summary
Electromed, Inc. (ELMD) announced that its President and CEO, Jim Cunniff, and CFO, Brad Nagel, will attend the 2024 Lytham Partners Investor Select Conference on February 1, 2024. The management team will participate in a fireside chat and investor 1x1s, with the fireside chat scheduled for 11 am Eastern Time. Interested parties can register for the fireside chat using the provided link.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.6%
Tags
conferences

FAQ

What is the current stock price of Electromed (ELMD)?

The current stock price of Electromed (ELMD) is $24.19 as of April 1, 2025.

What is the market cap of Electromed (ELMD)?

The market cap of Electromed (ELMD) is approximately 204.9M.

What is the primary focus of Electromed Inc?

Electromed Inc specializes in developing, manufacturing, and marketing medical devices focused on airway clearance therapy, predominantly through its SmartVest system which utilizes high frequency chest wall oscillation (HFCWO).

How does the SmartVest system work?

The SmartVest system employs a programmable air pulse generator connected to a wearable garment, delivering controlled chest wall oscillation that facilitates effective mucus clearance for patients with respiratory conditions.

What conditions can benefit from Electromed's technology?

Patients suffering from conditions such as COPD, cystic fibrosis, bronchiectasis, atelectasis, and various neuromuscular disorders can benefit from the airway clearance therapy provided by the SmartVest system.

Which regulatory standards does Electromed adhere to?

Electromed is accredited by the Joint Commission and holds certifications including ISO 13485:2003 and ISO 9001:2008, ensuring adherence to rigorous quality and safety standards in its manufacturing processes.

How does Electromed differentiate itself from competitors?

The company distinguishes itself through its innovative use of HFCWO technology, a strong commitment to clinical efficacy, and a robust quality management system that ensures patient safety and product reliability.

What is the significance of HFCWO in respiratory care?

High frequency chest wall oscillation (HFCWO) is a critical technology that enhances airway clearance by delivering effective yet comfortable treatment, offering an improved alternative to traditional chest physiotherapy methods.

Who are the primary customers of Electromed's products?

The company primarily serves healthcare providers, clinics, and institutions focused on respiratory care, as well as patients who require effective airway clearance as part of their treatment regimens.

What role do clinical validations play in Electromed's offerings?

Clinical validations ensure that Electromed's products meet strict efficacy and safety benchmarks, reinforcing the company's reputation for reliability and reinforcing trust among healthcare professionals.
Electromed

NYSE:ELMD

ELMD Rankings

ELMD Stock Data

204.85M
6.82M
20.54%
43.56%
2.44%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
NEW PRAGUE